The Swiss drugmaker is anticipated to report full-year sales of $54.82 billion, according to consensus estimates provided by Visible Alpha, marking a notable increase from the $50.32 billion recorded in 2024. Core operating profit—a key metric for the company that excludes exceptional items—is expected to reach $21.85 billion. This financial momentum follows a strong year for shareholders, during which Novartis stock climbed 22% to reach 117.24 Swiss francs.

To offset the inevitable loss of revenue from expiring drug patents, Novartis has pivoted toward high-stakes dealmaking. This shift was underscored in October by a $12 billion agreement to acquire Avidity Biosciences, a move intended to bolster its future pipeline. Investors are closely monitoring the company's external investment criteria as it seeks to fill the gap left by blockbuster treatments now facing generic competition.

Strategic Acquisitions and the 2030 Roadmap

According to analysts at JPMorgan, the group’s long-term prospects remain subject to uncertainty regarding its drug pipeline. Novartis has set a target for annual sales growth of 5% to 6% through 2030, aiming for a total revenue figure of $72.41 billion. Meeting these goals will require several key factors:

• The successful clinical progression of multiple new treatment candidates.
• Continued mitigation of generic competition for its core heart-failure franchise.
• Strategic integration of recently acquired biotech assets.

Despite solid third-quarter performance, the threat from generic manufacturers is an enduring challenge. Vontobel analyst Stefan Schneider noted that while the company has managed the initial impact of competition in the heart-failure market, the pressure is unlikely to dissipate. As the company looks beyond the current fiscal year, the sustainability of its growth beyond the turn of the decade remains the central question for the market.